Koers Oncobiologics Inc Nasdaq
Aandelen
US68235M2044
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
Omzet 2024 * | - | Omzet 2025 * | 9,53 mln. 8,91 mln. | Marktkapitalisatie | 180 mln. 168 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -121 mln. -113 mln. | Nettowinst (verlies) 2025 * | -64 mln. -59,79 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 18,8 x |
K/w-verhouding 2024 * |
-1,52
x | K/w-verhouding 2025 * |
-3,44
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 62,99% |
Recentste transcriptie over Oncobiologics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 07-07-21 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-15 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 13-04-18 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 11-12-15 |
C. Trenary
CEO | Chief Executive Officer | 66 | 07-07-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,80% | 53,67 mld. | |
+34,29% | 38,86 mld. | |
-8,05% | 38,76 mld. | |
-8,98% | 27,27 mld. | |
+10,69% | 25,91 mld. | |
-16,21% | 20,29 mld. | |
+31,00% | 12,78 mld. | |
+28,51% | 12,18 mld. | |
-1,67% | 11,96 mld. |
- Beurs
- Aandelen
- Koers OTLK
- Koers